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Background: The phenotypic spectrum of many rare disorders is much wider than previously considered.
Mucopolysaccharidosis type III (Sanfilippo syndrome, MPS III), is a lysosomal storage disorder traditionally considered
to be characterized by childhood onset, progressive neurocognitive deterioration with a rapidly or slowly
progressing phenotype. The presented MPS III case series demonstrates adult onset phenotypes with mild cognitive
impairment or non-neuronopathic phenotypes.
Methods: In this case series all adult MPS III patients with a mild- or non-neuronopathic phenotype, who attend
the outpatient clinic of 3 expert centers for lysosomal storage disorders were included. A mild- or non-
neuronopathic phenotype was defined as having completed regular secondary education and attaining a level of
independency during adulthood, involving either independent living or a paid job.
Results: Twelve patients from six families, with a median age at diagnosis of 43 years (range 3–68) were included
(11 MPS IIIA, 1 MPS IIIB). In the four index patients symptoms which led to diagnostic studies (whole exome
sequencing and metabolomics) resulting in the diagnosis of MPS III; two patients presented with retinal dystrophy,
one with hypertrophic cardiomyopathy and one with neurocognitive decline. The other eight patients were
diagnosed by family screening. At a median age of 47 years (range 19–74) 9 out of the 12 patients had normal
cognitive functions. Nine patients had retinal dystrophy and 8 patients hypertrophic cardiomyopathy.
Conclusion: We show the very mild end of the phenotypic spectrum of MPS III, ranging from late-onset stable
neurocognitive impairment to a fully non-neuronopathic phenotype. Awareness of this phenotype could lead to
timely diagnosis and genetic counseling.
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In recent years, clinical and diagnostic studies have dem-
onstrated that the phenotypic spectrum of many rare
lysosomal storage disorders is much wider than previ-
ously thought. Mucopolysaccharidosis type III (MPS III
or Sanfilippo syndrome), an autosomal recessive lyso-
somal storage disorder which is primarily characterized
by progressive neurocognitive deterioration, is nowadays
divided in a rapidly progressing and slowly progressing
phenotype [1]. MPS III is caused by a deficiency of one
of four enzymes involved in the stepwise degradation of
the glycosaminoglycan (GAG) heparan sulfate (HS) [2].
Four different subtypes of MPS III are recognized (MPS
IIIA-D), all resulting in HS accumulation in the central
nervous system (CNS) triggering a secondary patho-
physiological cascade with neuronal inflammation, apop-
tosis, astrocytosis, microgliosis and synaptic
disorganization [3, 4]. Classical MPS III is clinically di-
vided in three disease phases [1]. After an initial
symptom-free phase, a developmental delay is generally
noted at the age of 2–6 years. During the second phase,
progressive loss of cognition, behavioral and sleeping
problems manifest. During the third phase, generally
starting in their teens, progressive motor deterioration
results in complete dependency and loss of ambulation
[5]. Most patients demise in their second or third decade
of life [6]. Somatic disease is typically limited but may
involve recurrent ear-, nose- and throat- (ENT) disor-
ders, femoral head necrosis, hepatomegaly and, recently
reported, subclinical cardiac abnormalities [5, 7, 8]. A
characteristic sign of MPS III are the dysmorphic fea-
tures including progressive facial coarsening with prom-
inent eyebrows and hair, a protruding philtrum, and in
some synophrys and hypertrichosis.Although all patients
generally follow the same disease course, patients with a
more attenuated, slowly progressing, phenotype have
been described over the last decades [9–11]. In MPS
IIIA (OMIM #252900) homozygosity for the missense
mutations c.897C > T, p.(Ser298Pro) and c.617G > C,
p.(Arg206Pro) in the sulfamidase (SGSH) gene resulted
in an attenuated phenotype with a later onset of regres-
sion, a slower progression of neurocognitive decline, and
a longer survival [12–14]. An attenuated phenotype has
also been reported in patients with MPS IIIB (OMIM
#252920) due to the missense changes p.(Arg643Cys),
p.(Ser612Gly), p.(Glu634Lys), p.(Leu497Val) with stable
intellectual disability for many years [10, 15]. Further-
more, two case reports previously reported three pa-
tients with an even more attenuated phenotype,
presenting with cardiomyopathy, retinitis pigmentosa
and adult-onset dementia [16, 17].
In this manuscript we report a multi-center case series
of MPS III patients with a mild- or non-neuropathic
phenotype defined as having completed regularsecondary education and maintaining a level of indepen-
dency during adulthood, further delineating the very
mild end of the phenotypic spectrum, beyond the slowly
progressing phenotype.
Methods
All adult MPS III patients attending the outpatient clinic
of one of three expert centers for lysosomal storage dis-
orders, with a mild- or non-neuropathic phenotype were
included in this case series. This mild- or non-
neuropathic phenotype was defined as: 1) a completed
regular secondary education and 2) independency during
adulthood, involving either independent living or a paid
job.
Diagnosis of MPS III was confirmed by investigation
of urinary GAG levels (total or HS), enzymatic activity
in leucocytes and/or fibroblasts and mutation analysis.
Patient data were obtained from the following centers:
Amsterdam University Medical Centers (Amsterdam
UMC), The Rotterdam Eye Hospital, Erasmus Medical
Center (all in the Netherlands), and Salford Royal NHS
Foundation Trust (United Kingdom). Educational level
was divided into three categories: low (primary, lower
vocational, lower and middle general secondary educa-
tion), intermediate (middle vocational, higher general,
pre-university education) and high (higher vocational
education and university) [18].This study was presented
to the medical ethical committee of the Amsterdam
UMC who declared that this study needed no ethical ap-
proval since this study entails a retrospective and anon-
ymized chart review. Written informed consent for
publication of the case histories and the photographs
was obtained from all patients and, if legally obliged,
from their parents and/or legal representatives.
In addition, the literature was reviewed for patients
with a mild neuronopathic phenotype fulfilling the above
criteria, in order to present a complete overview.
Results
Patient characteristics
Twelve patients from six families were included in this
case series (Table 1). The median age at inclusion was
47 years (range 19–74). Median age at diagnosis was 43
years (range 3–68). Four patients were males (33%).
Eleven patients were diagnosed with MPS IIIA and one
with MPS IIIB.
Symptom leading to diagnostic investigations
In the six families, the index patients initiating the diag-
nostic tests were retinal dystrophy in two index patients,
hypertrophic cardiomyopathy (HCM) in one and a de-
cline in neurocognitive functioning in three, of which
two had a classical progressive phenotype and are there-
fore not included in this cohort. The diagnostic
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quencing (WES) in 4 families and metabolic studies in
the other 2 families.
Metabolic studies
Urinary GAG levels were increased in all patients, and
enzymatic activity in leucocytes or fibroblasts was mark-
edly decreased and clearly within the patients range in
all patients, confirming the diagnosis of MPS III in all
twelve patients.
Missense variants
In total, 7 different missense changes in the SGSH gene
were reported of which 5 have previously been reported
as pathogenic (p.(Ser298Pro), p.(Arg74Cys),
p.(Glu355Lys), p.(Arg245His), p.(Arg377His)) [13, 19–
21]. The other two variances of unknown significance
are likely pathogenic based on in-silico analysis
(p.(Arg182His): PhyloP 5.13 (conserved), CADD 22.9
(damaging, cut-off> 20) and p.(Thr421Arg): PolyPhen-2
0.98 (probably damaging, cut-off > 0.8), M-CAP 0.225
(damaging, cut-off >.025), CADD 20.7 (damaging, cut-
off > 20), Provean −3.39 (damaging, cut-off −2.5), LRT
(deleterious), MutationTaster (damaging)) [22]. Two
missense changes in the NAGLU gene were found, both
previously reported as pathogenic (p.(Arg643Cys) and
p.(Ser612Gly)) [23, 24].
Cases from the literature
Three cases with a comparably mild phenotype were
previously reported in the literature, presented in
Table 1. Mutation analysis was not mentioned for these
patients.
Neurocognitive testing
Neurocognitive testing had been recently performed in 8
of the 12 patients reported here, and were reported in 2
of the 3 patients reported in the literature (Table 2).
Brief clinical history and highest attained educational
level and achievements of patient cohort
Family 1
In this family 5 siblings are affected. Patient 1 is the
index patient. Patients 2–5 were diagnosed by family
screening.
Patient 1 This female patient was diagnosed with MPS
IIIA by WES, at the age of 64 after evaluation for retinal
dystrophy. Retinal dystrophy could not otherwise be ex-
plained. She has a completely normal cognitive function-
ing (Table 2). After the diagnosis, additional follow-up
revealed an asymptomatic severe left ventricle hyper-
trophy (LVH) with a good cardiac function. Her highest
completed educational level is middle vocationaleducation (intermediate education level). She is currently
65 years old and performed the financial administration
of her husband’s company until her recent retirement.
She is the mother of three healthy children. She has her
driver’s license, but can no longer drive due to loss of vi-
sion. She has no dysmorphic features (Fig. 1e).
Patient 2 Patient 2 was diagnosed at the age of 56 years.
Her symptom at diagnosis was retinal dystrophy present-
ing with visual impairment. Her medical history men-
tioned moderate LVH with transient palpitations. She
completed lower secondary education (low educational
level), is married and has three healthy children. She has
a completely normal cognitive functioning (Table 2).
Momentarily she is on sick-leave since she is unable to
work and lost her driver’s license following visual im-
pairment. She has no dysmorphic features (Fig. 1f).
Patient 3 This female was diagnosed at the age 62 years.
She was already known with asymptomatic HCM after a
routine electrocardiography checkup. After diagnosis of
MPS III she was diagnosed with asymptomatic retinal
dystrophy. She has mild hepatomegaly on ultrasound.
She has a Bachelor of Science degree in teaching (high
educational level) and works as a primary school teacher.
She refused neurocognitive testing since she experiences
no issues with her cognition. She is married and has five
healthy children. She has her driver’s license. She has no
dysmorphic features.
Patient 4 This patient was diagnosed at the age of 51
years. At diagnosis he expressed visual impairment after
which retinal dystrophy was diagnosed, in addition to
mild asymptomatic LVH and mild hepatomegaly. He
completed lower secondary education (low educational
level) and runs his own company. He refused formal
cognitive testing as he was too busy. He has his driver’s
license. He has no dysmorphic features.
Patient 5 This patient was diagnosed at the age of 63
years. Her medical history mentioned moderate HCM
and she was diagnosed with asymptomatic mild retinal
dystrophy following family screening. She completed
upper secondary school (intermediate educational level)
and works as a secretary. She is married and has three
healthy children. She has a completely normal cognitive
functioning (Table 2). She has her driver’s license. She
has no dysmorphic features.
Family 2
In this family 2 siblings are affected who were both diag-
nosed as part of family screening. The index patient was
a nephew with a classic progressive phenotype who was
therefore not included in this cohort.
Table 2 Neurocognitive test results in MPS III patients with a mild- or non-neuropathic phenotype
Patient Age at Testing (years) Test Domain Index scores 95% CI
1.1 a 64 WAIS-IV short form VCI 111 105–116
PRI 85 75–94
2.1 a 55 WAIS-IV short form VCI 93 88–99
PRI 125 116–131
5.1 a 54 WAIS-IV short form VCI 100 94–106
PRI 116 107–122
6.2 c 20 WAIS-IV FSIQ b 79 75–85
VCI 109 103–114
WMI 80 74–89
PRI 72 66–81
PSI 59 54–73
7.2 18 WAIS-IV FSIQ b 96 91–101
VCI 113 107–118
WMI 92 85–100
PRI 100 92–108
PSI 76 69–88
8.3 50 WAIS-IV short form VCI 93 88–99
10.4 c 26 WAIS-III FSIQ b 68 65–73
VCI 79 74–85
WMI 68 63–77
PRI 61 56–72
PSI 55 51–69
11.5 c 42 WAIS-IV FSIQ 50 47–55
VCI 66 62–73
WMI 55 51–64
PRI 52 48–61
PSI 50 47–63
Cases from literature
1 [17] 31 WAIS FSIQ 88 NK
2 [17] 36 WAIS FSIQ 75 NK
Neurocognitive test scores are based on a mean of 100 with a SD of 15.
Abbreviations: FSIQ full scale IQ; NK not known; PRI perceptual reasoning index; PSI processing speed index; VCI verbal comprehension index; WAIS Wechsler Adult
Intelligence Scale; WMI working memory index.
a VCI and PRI estimated using the proration method [25], extrapolating the scores on 2 subtest within each index.
b FSIQ should be interpreted with caution given significant discrepancies between the index scores for the different components.
c Functions with a mild neurocognitive impairment.
Nijmeijer et al. Orphanet Journal of Rare Diseases          (2019) 14:249 Page 5 of 10Patient 6 This male was diagnosed at the age of 5 years.
His mother insisted on metabolic testing for MPS III as
she felt that his school performance did not meet the ex-
pected level based on the educational level of his par-
ents, and MPS IIIA was diagnosed in his nephew (slowly
progressing phenotype, (p.(Arg245His) / p.(Ser298Pro)).
Despite the fact that the consulted experienced meta-
bolic pediatrician did not observe any signs or symptoms
leading to a suspicion of MPS III, urinary GAG screen-
ing was performed. His highest completed education
was middle vocational education (intermediate educationlevel). He is currently 21 years old, has a supervised job
and lives with his parents. He studied for his driver’s li-
cense but failed for the theoretical exam. He has an im-
paired processing speed on neurocognitive testing
(Table 2). He wears glasses for a refractive error leading
to good vision. A cardiac ultrasound showed no abnor-
malities. He has no dysmorphic features (Fig. 1a).
Patient 7 This male was tested at the age of 3 years in
the absence of any signs or symptoms of MPS III as part
of family screening. He is now 19 years old and
A B C
D E F
Fig. 1 Mucopolysaccharidosis type III patients without typical or very mild dysmorphic features. a. Type IIIA; 21 years. b. Type IIIA, 19 years. c. Type
IIIB; 32 years. d. Type IIIA; 42 years. e. Type IIIA; 65 years. f. Type IIIA; 56 years
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which corresponds with an intermediate educational
level. He has a normal cognitive functioning (Table 2).
He has no vision problems and a cardiac ultrasound
showed no abnormalities. This patient has no dys-
morphic features (Fig. 1b).
Family 3
In this family 2 siblings are affected. Patient 8 is the
index patient. Patient 9 was diagnosed as part of family
screening.
Patient 8 This female patient was diagnosed with MPS
IIIA by WES, at the age of 49 years, after evaluation of
retinal dystrophy by the ophthalmologist (L.I.B.) involved
in the diagnosis of family 1. Further studies showed
asymptomatic but severe HCM and mild hepatomegaly
on ultrasound. She completed upper secondary school
(intermediate educational level). She is currently on sick
leave with visual impairment and she can no longer
drive. She has no cognitive complaints and has a normal
cognitive functioning (Table 2). She is married and has a
healthy son. She has no dysmorphic features.
Patient 9 This patient was diagnosed at the age of 41
years following family screening. She had no medicalhistory but reported some visual impairment and was di-
agnosed with retinal dystrophy after the diagnosis of
MPS III, in addition to mild LVH. She has a Bachelor of
Science degree (high educational level) and runs her
own company. She refused neurocognitive testing as she
had no cognitive complaints. She has two healthy chil-
dren. She has her driver’s license. She has no dys-
morphic features.Family 4
In this family 2 siblings are affected. Patient 10 was diag-
nosed as part of family screening. The index patient, her
5 year older sister, had followed special education from
the age of 8 years and had progressive cognitive decline
leading to diagnostic studies by WES. Therefore, the
index patient has not been included in this cohort.Patient 10 This female patient was diagnosed at age 27
with MPS IIIB following family screening. At the time of
diagnosis patient 10 functioned with a stable, mild neu-
rocognitive delay (Table 2). Her highest completed level
of education is middle vocational education (intermedi-
ate education level). She is currently 34 years old and
has a supervised job. She lives in an assisted living facil-
ity. She has no abnormalities on cardiac ultrasound and
Nijmeijer et al. Orphanet Journal of Rare Diseases          (2019) 14:249 Page 7 of 10no vision complaints. She has no dysmorphic features
(Fig. 1c).Family 5
In this family 2 siblings are affected. His older brother
has a more severe phenotype and was therefore not in-
cluded in this cohort.Patient 11 This male patient was diagnosed with MPS
IIIA by WES, following a decline in neurocognitive im-
pairment at the age of 41 years which became apparent
after a deterioration in daily activities. He was diagnosed
with retinitis pigmentosa following impairment of night
vision in his late teens. He had successfully completed
comprehensive secondary school (year 11–16) but did
not sit final exams. He lived with his parents until the
age of 37. After this, he lived in an assisted living accom-
modation. He was able to travel independently until the
age of 37. He has some mild dysmorphic characteristics
which may fit the diagnosis of MPS III (Fig. 1d).Family 6
In this family there is 1 patient included, the index
patient.Patient 12 This patient was diagnosed at the age of 68
with symptomatic moderate HCM. Metabolic testing
was performed after an unremarkable gene panel for
HCM, and led to the diagnosis of MPS IIIA. Her medical
history mentioned unexplained visual impairment at age
59, but was later diagnosed as retinal dystrophy. She has
completed lower vocational education (low educational
level) and has worked until her retirement. She is mar-
ried and has two healthy children. Neurocognitive test-
ing was not performed since she had no cognitive
complaints. She has no dysmorphic features.Cases from the literature
Previously, as far as we know, two case reports have
been published reporting on MPS III patients with com-
parably mild phenotypes (Table 1). The first case report
describes a MPS IIIA patient who presented at the age
of 53 years with a hypertrophic cardiomyopathy without
any neurocognitive problems [16]. The diagnosis was
established after an endomyocardial biopsy which re-
vealed storage vacuoles with acid mucopolysaccharides.
This patient worked as a schoolteacher. Another report
describes two sisters with MPS IIIC, who were asymp-
tomatic until their third decade of life [17]. They were
diagnosed at ages 42 and 46 years because of adult onset
dementia and retinitis pigmentosa. Both had followed
normal secondary education.Discussion
We report 12 adult patients from 6 families with an un-
usual presentation of MPS III. In contrast to patients
with the classical phenotype of MPS III, these patients
showed a remarkable late-onset and mild cognitive im-
pairment, and some patients with a non-neuronopathic
phenotype consisting of retinal dystrophy and/or HCM.
This indicates that these and the three previously re-
ported cases with such an attenuated phenotype are all
part of a mild- or non-neuropathic phenotype of MPS
III [16, 17]. All twelve patients completed a normal sec-
ondary education. At last follow-up, at a median age of
47 years, only three patients (6.2, 10.4, 11.5) had a mild
neurocognitive impairment including one with a slow
decline after the age of 41 years. All other patients have
a normal cognitive functioning. Only one patient has
mild facial coarsening which is characteristic for MPS
III; all others patients have normal features.
Before diagnosis, visual impairment due to retinal dys-
trophy was present in four patients and symptoms due to
cardiomyopathy also in four patients. One of these pa-
tients had a combination of clinical symptoms due to both
retinal dystrophy and cardiomyopathy. After diagnosis of
MPS III, retinal dystrophy and hypertrophic cardiomyop-
athy were detected in nine and eight patients respectively.
While none of these symptoms has been reported as a
presenting symptom in patients with the more common
rapid progressing phenotype, both retinal dystrophy [25,
26] and LVH and HCM [27, 28] have been reported to
occur during the course of the disease in patients with
both phenotypes. Pericentral retinitis pigmentosa, a spe-
cific subtype of retinal dystrophy, has been observed as
sole symptom in association with mutations in the
HGSNAT gene, encoding the lysosomal enzyme heparin-
alpha-glucosaminide N-acetyltransferase a deficiency of
which causes MPS IIIC (OMIM #252930) [29, 30]. Unfor-
tunately, neither urinary GAG levels nor the activity of the
involved enzyme (were investigated or reported in these
studies. We now show that both retinal dystrophy with se-
vere visual impairment and clinically relevant hyper-
trophic cardiomyopathy can be the only presenting
symptoms in MPS IIIA. We hypothesize that prolonged
exposure to slowly accumulating HS may lead to retinal
degeneration and cardiomyopathy. Indeed, a recent study
showed subclinical left ventricular dysfunction, assessed
by speckle-tracking echocardiography, in patients with the
rapidly and slowly progressing phenotypes [31].
In eight patients in this study cognitive testing had re-
cently been performed. In four of them there were no
signs of cognitive impairment and cognitive assessment
was done only because of the diagnosis of MPS III.
Three patients showed remarkable disharmonic profiles
generally in favor of verbal comprehension with very low
processing speed. Disharmonic profiles have previously
Nijmeijer et al. Orphanet Journal of Rare Diseases          (2019) 14:249 Page 8 of 10been described in more severely affected MPS III pa-
tients [32].
While significant sibling disparity has not been re-
ported in MPS III, we observed striking differences be-
tween patient 10.4, with mild cognitive problems in
adulthood, and her older sibling who had progressive
loss of cognitive function from the age 8 years. Patient
11.5 also has a sibling with a more classical course of the
disease who is now non-ambulant and fully care
dependent. Probably, other (epi) genetic and/or environ-
mental factors influence the course of the disease more
profoundly in patients with genotypes that may convey a
very mild phenotype than in those that convey a more
severe phenotype.
Our study has limitations, as only patients attending
one of the participating centers were included. We thus
cannot estimate the prevalence of the mild- and/or non-
neuropathic MPS III phenotypes in the population. Al-
though we cannot exclude founder effects causing the
occurrence of these remarkably mild phenotypes in the
Netherlands and the UK, we feel that the wide availabil-
ity of WES for clinical diagnostic purposes in these
countries is the most important factor for diagnosis. We
therefore expect that these patients are not unique and
confined to our countries, and that MPS III patients
with a similar mild- or non-neuropathic phenotype will
often miss proper diagnosis. Even when WES is used as
diagnostic strategy, MPS III might well be missed, as
WES panels generally only include genes known to be
involved in specific conditions such as cardiomyopathy
or retinal degeneration, and these panels will most often
not include MPS III genes. Based on our study, we feel
that WES data extraction for these indications should be
expanded with MPS III genes when the targeted gene
panel if not conclusive.
It is important to diagnose mild - and non-
neuronopathic MPS III patients for several reasons. First,
such a diagnosis will allow monitoring for potential add-
itional complications, such as for HCM in patients with
retinal dystrophy as a first symptom and vice versa. Sec-
ond, a diagnosis of MPS III allows for genetic counseling
of relatives, thus enhancing reproductive autonomy [33].
Third, a phase IIB study in MPS IIIA patients concluded
that intrathecal enzyme replacement therapy (ERT) did
not sufficiently alter CNS disease, but that ERT may
have somatic efficacy [34]. Intravenous ERT might be a
successful treatment in MPS III patients with cardiomy-
opathy, as ERT was demonstrated as effective by redu-
cing left ventricular mass index in children with Pompe
disease [35]. Furthermore, a number of disease modify-
ing therapies are currently under investigation for the
CNS disease of MPS III, and some are already in clinical
trial including both gene therapy and ERT [36–40]. Pa-
tients with a very slow evolution of disease may well beeven more responsive to treatment than the patients
with the classical rapidly progressing phenotype, as the
therapeutic window in this latter group is small [1].
However, it will be very difficult, if not impossible, to as-
sess treatment efficacy in patients with such slowly pro-
gressing phenotypes by clinical evaluation and this can
probably only be done by following a biomarkers re-
sponse. Unfortunately, to date no biomarker for MPS
III, correlating with disease progression, has been
identified.
Conclusions
In conclusion, MPS III can present at adult age with a
remarkably mild and late onset neurocognitive impair-
ment or even non-neuronopathic somatic phenotype
with either retinal dystrophy or hypertrophic cardiomy-
opathy. Awareness of this phenotype is essential as pa-
tients and families can benefit from diagnosis as this
leads to appropriate diagnostic strategies, monitoring,
family counseling and, hopefully within the next de-
cades, treatment. We strongly advise to add MPS III
genes as a second diagnostic panel in targeted gene
panels for retinal dysfunction and cardiomyopathy.
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